These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 19731874)
1. [Treatment of dyslipidemia in patients with metabolic syndrome and chronic kidney disease]. Monhart V Vnitr Lek; 2009; 55(7-8):671-8. PubMed ID: 19731874 [TBL] [Abstract][Full Text] [Related]
2. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Fazio S Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268 [TBL] [Abstract][Full Text] [Related]
3. Fibrates in combination with statins in the management of dyslipidemia. Jacobson TA; Zimmerman FH J Clin Hypertens (Greenwich); 2006 Jan; 8(1):35-41; quiz 42-3. PubMed ID: 16407687 [TBL] [Abstract][Full Text] [Related]
4. Fibrates: where are we now? Seth Loomba R; Arora R Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670 [TBL] [Abstract][Full Text] [Related]
5. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe? Milionis H Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564 [TBL] [Abstract][Full Text] [Related]
6. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome? Turhan H; Yetkin E Int J Cardiol; 2006 Jun; 110(2):276-7. PubMed ID: 16364471 [TBL] [Abstract][Full Text] [Related]
7. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Tenenbaum A; Fisman EZ; Motro M; Adler Y Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798 [TBL] [Abstract][Full Text] [Related]
8. The role of fenofibrate in clinical practice. Zambon A; Cusi K Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056 [TBL] [Abstract][Full Text] [Related]
9. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia]. Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665 [TBL] [Abstract][Full Text] [Related]
11. [Diabetic dyslipidaemia and the atherosclerosis]. Márk L; Dani G Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274 [TBL] [Abstract][Full Text] [Related]
12. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis. Choi HD; Shin WG Curr Med Res Opin; 2014 Jan; 30(1):1-10. PubMed ID: 24063624 [TBL] [Abstract][Full Text] [Related]
14. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy. Athyros VG; Tziomalos K; Karagiannis A Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164 [TBL] [Abstract][Full Text] [Related]
18. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials. Geng Q; Ren J; Chen H; Lee C; Liang W Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878 [TBL] [Abstract][Full Text] [Related]
19. Lipid lowering in liver and chronic kidney disease. Herrick C; Litvin M; Goldberg AC Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):339-52. PubMed ID: 24840263 [TBL] [Abstract][Full Text] [Related]
20. Safety considerations with fenofibrate/simvastatin combination. Filippatos TD; Elisaf MS Expert Opin Drug Saf; 2015; 14(9):1481-93. PubMed ID: 26134595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]